Psychedelics Promote Structural and Functional Neural Plasticity
Calvin Ly,Alexandra C. Greb,Lindsay P. Cameron,Jonathan M. Wong,Eden V. Barragan,Paige C. Wilson,Kyle F. Burbach,Sina Soltanzadeh Zarandi,Alexander Sood,Michael R. Paddy,Whitney C. Duim,Megan Y. Dennis,A. Kimberley McAllister,Kassandra M. Ori-McKenney,John A. Gray,David E. Olson +15 more
Reads0
Chats0
TLDR
It is reported that, like ketamine, serotonergic psychedelics are capable of robustly increasing neuritogenesis and/or spinogenesis both in vitro and in vivo.About:
This article is published in Cell Reports.The article was published on 2018-06-12 and is currently open access. It has received 436 citations till now.read more
Citations
More filters
Journal ArticleDOI
A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties:
Rachael L. Sumner,Emme Chacko,Rebecca McMillan,Meg J. Spriggs,Christie Anderson,James Chen,Amelia French,SungHun Jung,Akshaya Rajan,Gemma Malpas,John Hay,Rhys Ponton,Suresh D. Muthukumaraswamy,Frederick Sundram +13 more
TL;DR: Ketamine is central to one of the most rapidly growing areas of neuroscientific research into novel treatments for depression as discussed by the authors, and limited research has indicated that the psychedelic propert...
Journal ArticleDOI
Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.
Daniel Perkins,Jerome Sarris,Jerome Sarris,Susan L. Rossell,Susan L. Rossell,Yvonne Bonomo,Yvonne Bonomo,David Forbes,Christopher G. Davey,Daniel Hoyer,Daniel Hoyer,Colleen Loo,Colleen Loo,Greg Murray,Sean Hood,Violeta Schubert,Nicole Leite Galvão-Coelho,Meaghen O'Donnell,Olivia Carter,Paul Liknaitzky,Martin Williams,Dan Siskind,David G Penington,Michael Berk,David J. Castle +24 more
TL;DR: In this article, the authors reflect upon the 'Clinical Memorandum on Psychedelics' recently released by the Royal Australian and New Zealand College of Psychiatrists and note subsequent developments including the application for down-scheduling of psilocybin and 3,4-methylenedioxymethamphetamine presently being considered by the Therapeutic Goods Administration and approvals for access via the Special Access Scheme.
Journal ArticleDOI
Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits.
Soledad Marton,Bruno González,Sebastián Rodríguez-Bottero,Ernesto Miquel,Laura Martínez-Palma,Mariana Pazos,José Pedro Prieto,Paola Rodríguez,Dalibor Sames,Gustavo Seoane,Cecilia Scorza,Patricia Cassina,Ignacio Carrera +12 more
TL;DR: Results show for the first time a selective increase of GDNF specifically in the VTA for I40 but not for I20 after 24 h of administration, which agrees with the effective dose found in previous self-administration studies in rodents.
Book ChapterDOI
An introduction to psychedelic neuroscience
Tanya Calvey,Fleur M. Howells +1 more
TL;DR: This chapter is an introduction to the volume "Psychedelic Neuroscience" of Elsevier's Progress in Brain Research addressing the neurobiological mechanisms of psychedelic drugs, the resulting changes in brain activity and integration of traditional viewpoints.
References
More filters
Journal ArticleDOI
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.
Harvey Whiteford,Harvey Whiteford,Louisa Degenhardt,Louisa Degenhardt,Juergen Rehm,Juergen Rehm,Amanda J Baxter,Amanda J Baxter,Alize J. Ferrari,Alize J. Ferrari,Holly E. Erskine,Holly E. Erskine,Fiona J Charlson,Fiona J Charlson,Rosana E. Norman,Rosana E. Norman,Abraham D. Flaxman,Nicole E. Johns,Roy Burstein,Christopher J L Murray,Theo Vos +20 more
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) as discussed by the authors was used to estimate the burden of disease attributable to mental and substance use disorders in terms of disability-adjusted life years (DALYs), years of life lost to premature mortality (YLLs), and years lived with disability (YLDs).
Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
TL;DR: The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.
Journal ArticleDOI
A simple practice guide for dose conversion between animals and human.
Anroop B. Nair,Shery Jacob +1 more
TL;DR: This review provides basic information about translation of doses between species and estimation of starting dose for clinical trials using allometric scaling and the method of calculation of injection volume for parenteral formulation based on human equivalent dose.
Journal ArticleDOI
Antidepressant effects of ketamine in depressed patients
Robert M. Berman,Angela Cappiello,Amit Anand,Amit Anand,Dan A. Oren,Dan A. Oren,George R. Heninger,Dennis S. Charney,Dennis S. Charney,John H. Krystal,John H. Krystal +10 more
TL;DR: A first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression suggests a potential role for NMDA receptor-modulating drugs in the treatment of depression.
Journal ArticleDOI
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
Carlos A. Zarate,Jaskaran Singh,Paul J. Carlson,Nancy E. Brutsche,Rezvan Ameli,David A. Luckenbaugh,Dennis S. Charney,Husseini K. Manji +7 more
TL;DR: Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.